PhaseBio Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

PhaseBio Pharmaceuticals

16/05/2022 22:06

* PhaseBio Pharmaceuticals Inc  PHAS.OQ  reported a
quarterly
adjusted loss of 23 cents​​ per share for the quarter ended in
March. The mean expectation of five analysts for the quarter was
for a loss of 66 cents per share.
    * Revenue was $117.00 thousand​;  analysts expected $2.33
million. 
    * PhaseBio Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of 23 cents​.
    * The mean earnings estimate of analysts had fallen by
about 14.6%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * PhaseBio Pharmaceuticals Inc shares had fallen by 22.0%
this
quarter and lost 60.5% so far this year.
    * The company reported a quarterly loss of $11.14 million.
    * Wall Street's median 12-month price target for PhaseBio
Pharmaceuticals Inc is $15.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 16 at 09:06 p.m.  ​All
figures in US dollars unless otherwise stated